A COMPOUNDING PROBLEM
The pharmacy landscape has undergone a dramatic shift in recent years. This is largely due to a 2012 fungal meningitis outbreak that took 64 lives and injured another 751 across the United States. The culprit? A New England-based 797 Compounding Pharmacy that produced and distributed contaminated medications. Subject only to periodic general inspections by the Board of Pharmacy, compounding pharmacies do not meet the same protocols, sterility, and potency testing as FDA-registered facilities. The result is cheaper medications for purchasers and windfall profits for Compounding Pharmacies—all at the expense of patient safety.